参芪扶正注射液在晚期胃癌化疗中应用观察

Clinical study of Shenqi fuzheng injection in chemotherapy of advanced gastric cancer

目的：探讨XELOX方案化疗联合参芪扶正注射液治疗晚期胃癌毒副作用临床观察。方法：80例晚期胃癌患者随机分成对照组和治疗组对照组给予奥沙利铂联合卡培他滨治疗，共2周期（每周期21d）。治疗组为化疗联合参芪扶正注射液250mL每天一次，静滴d1~10。结果：治疗组和对照组近期有效率为62.5%VS57.5%，差异无统计学意义（P＞0.05），但治疗组生活质量高于对照组（P＜0.05）。对照组恶心、呕吐等消化道反应发生率高（P＜0.05），两者差异有统计学意义，而治疗组在治疗前后则无明显影响；在白细胞总数及粒细胞减少等方面，对照组下降明显（P＜0.05），治疗组则无较大影响。结论：参芪扶正注射液虽未能增加XELOX方案的近期临床缓解率，但明显降低药物引起的副作用的产生，提高患者生活质量，从而利于化疗顺利进行。

Objective：To observe the therapeutic effect of shenqi infection conbined with XELOX in treatment of advanced gastric cancer.Methods：80 patients with gastric cancer were randomly divided into control group and treating group. For the control group, patients were administrated with oxaliplatine and capecitabine 21d as a cycle, and 1 course of treatment consisted 2 cycles. For the treating group, 250 ml of shenqi fuinfection was given intravenously for 10days.Results：The short-time therapeutic efficacy was similar between the control and the treating group57.5% and 62.5%respectively （P〉0.05）. However, the content of WBC,eutrophilic granulocyte were decreased in control group, but no changes were observed in the treating group.The adverse effect, such as neurotoxicity were weaker for the treating group.Conclusion：Although Shenqi injection combined with XELOX may not increase the short-term clinical effects, but could decrease the adverse effect which were good for the patients＇ quality of life.